News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Enabling Capabilities of Inovio Biomedical Corporation’s Electroporation Delivery Technology with SIV DNA Vaccine Confirmed in Collaborative Study With National Cancer Institute
September 3, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
MORE ON THIS TOPIC
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
·
1 min read
·
Kate Goodwin
Phase III
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
December 12, 2024
·
1 min read
·
Annalee Armstrong
Cardiovascular disease
Keros Suspends Two Arms of Hypertension Study After Reports of Pericardial Effusion
December 12, 2024
·
2 min read
·
Tristan Manalac
Prostate cancer
Candel Stock Skyrockets on Promising Phase III Prostate Cancer Data
December 12, 2024
·
3 min read
·
Tristan Manalac
